Public Policy

DSA ADS Course - 2022

COVID19, Public Policy, Health Policy, mRNA Vaccines, Vaccines, Clinical Trial Design, Evidence Hierarchy

This is a FOIA document of the first 2.5 months after the vaccine roll-out. Discuss clinical trial design and hierarchy of evidence in context of mRNA vaccines.

5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

DSA ADS Course - 2022

COVID19, Public Policy, Health Policy, mRNA Vaccines, Vaccines, Clinical Trial Design, Evidence Hierarchy

Discuss clinical trial design and hierarchy of evidence in context of mRNA vaccines.

The Pfizer Inoculations Do More Harm Than Good - December, 2021

See also video: https://rumble.com/vqx3kb-the-pfizer-inoculations-do-more-harm-than-good.html

April, 2020

Abstract

December, 2021

Highlights

• Describes a novel causal Bayesian network approach for systematic product risk assessment.

• The approach resolves some limitations with current commonly used product risk assessment methods.

• The approach complements product risk assessment methods like RAPEX.

• The approach can produce quantified, auditable product risk assessment with limited or no testing data.

Abstract

December, 2021

Abstract

Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both COVID-19 infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajai, a Southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.

October, 2021

Abstract